Supplementary data for

Cocrystal formation by anti-solvent slurry

Yi Li, Shun-Yu Li, Xia-Lin Dai, Tong-Bu Lu, Jia-Mei Chen

Experimental section

Materials and general methods

CBZ was purchased from Shanghai Shengde Pharmaceutical Technology Co., Ltd. Malonic acid, succinic acid, glutaric acid, adipic acid, DL-malic acid, benzoic acid, cinnamic acid, salicylic acid, acetylsalicylic acid, vanillic acid, 2, 6pyridinedicarboxylic acid, benzamide, isonicotinamide, nicotinamide, saccharin and 4, 4'-bipyridine were purchased from Aladdin Reagent Inc. L(+)-tartaric acid, L-malic acid, 1-hydroxy-2-naphthoic acid, 4-hydroxybenzoic acid, 2, 4-dihydroxybenzoic acid, 2, 5-dihydroxybenzoic acid, 2, 6-dihydroxybenzoic acid, 4-hydroxybenzamide and naringenin were purchased from Energy Chemical. All other chemicals and solvents were commercially available and used as received. Powder X-ray Diffraction (PXRD) analysis was performed on a Rigaku MiniFlex 600 X-ray diffractometer equipped with a D/teX Ultra one-dimensional detector, using Cu Ka radiation ($\lambda = 1.541862$ Å) generated at 40 kV and 15 mA. Each sample was placed on a silicon disk and measured over an angular range of 3–40 ° (2 θ) with a step size of 0.0142° (2 θ) and a dwell time of 0.1 s. Thermogravimetric (TG) analysis was performed using a Netzsch TG 209F3 instrument under nitrogen atmosphere. Each sample was placed on an alumina crucible and heated from 40 °C to 500 °C at a heating rate of 10 °C/min. Differential scanning calorimetry (DSC) was recorded on a Netzsch DSC 200 F3 instrument with nitrogen atmosphere. Each sample was placed on an aluminum sample pan and heated from 40 °C to the decomposition temperature of the sample at a heating rate of 10 °C/min. ¹H nuclear magnetic resonance (¹H NMR) spectra were acquired on a Bruker 400 MHz spectrometer using dimethyl sulfoxide-d6 as solvent and TMS (0 ppm) as internal standard.

General procedure of each anti-solvent slurry experiment

A stoichiometric ratio mixture of CBZ and co-former (with the total mass of 20 mg) was added to 1 mL anti-solvent (*n*-heptane) with addition of 10-100 μ L (MeOH/MeCN/EtOAc/ACE). The resulting suspension was stirred under 600 rpm for 24-48 hours and was then filtered. The obtained solid was dried under air and was examined by PXRD.

Anti-solvent slurry experiment 1: CBZ-malonic acid cocrystal (2:1)

A stoichiometric mixture of CBZ (16.4 mg, 0.070 mmol) and malonic acid (3.6 mg, 0.035 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeON/10 μ L EtOAc/10 μ L ACE and left to stir for 24 hours at room temperature. A stoichiometric mixture of CBZ (0.82 mg, 0.0035 mmol) and malonic acid (0.18 mg, 0.0017 mmol) was added to 0.5 mL heptane with addition of 1 μ L MeOH and left to stir for 30 min at room temperature. A stoichiometric mixture of CBZ (18.0 g, 0.17 mol) was added to 500 mL heptane with addition of 50 μ L MeOH and left to stir for 30 min at room temperature.



Fig. S1 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments (a) with different solvents and (b) on varying scales of CBZ/malonic acid system.

Anti-solvent slurry experiment 2: CBZ-succinic acid cocrystal (2:1)

A stoichiometric mixture of CBZ (16.0 mg, 0.068 mmol) and succinic acid (4.0 mg, 0.034 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeOH/10 μ L MeOH/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S2 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/succinic acid system.

Anti-solvent slurry experiment 3: CBZ-glutaric acid cocrystal (1:1)

An equimolar mixture of CBZ (12.8 mg, 0.055 mmol) and glutaric acid (7.2 mg, 0.055 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeCN/10 μ L EtOAc/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S3 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/glutaric acid system.

Anti-solvent slurry experiment 4: CBZ-adipic acid cocrystal (2:1)

A stoichiometric mixture of CBZ (15.3 mg, 0.065 mmol) and adipic acid (4.7 mg, 0.032 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeCN/10 μ L EtOAc/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S4 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/adipic acid system.

Anti-solvent slurry experiment 5: CBZ-L(+)-tartaric acid cocrystal (1:1)

An equimolar mixture of CBZ (12.2 mg, 0.052 mmol) and L(+)-tartaric acid (7.8 mg, 0.052 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeOH/10 μ L MeOH/10 μ L ACE and left to stir for 48 hours at room temperature.



Fig. S5 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/L(+)-tartaric acid system.

Anti-solvent slurry experiment 6: CBZ-L-malic acid cocrystal (1:1)

An equimolar mixture of CBZ (12.8 mg, 0.054 mmol) and L-malic acid (7.2 mg, 0.054 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeCN/10 μ L EtOAc/10 μ L ACE and left to stir for 48 hours at room temperature.



Fig. S6 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/L-malic acid system.

Anti-solvent slurry experiment 7: CBZ-DL-malic acid cocrystal (1:1)

An equimolar mixture of CBZ (12.8 mg, 0.054 mmol) and DL-malic acid (7.2 mg, 0.054 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeOH/10 μ L MeOH/10 μ L ACE and left to stir for 24 hours at room temperature.





Fig. S7 (a) PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/DLmalic acid system. (b) ¹H NMR spectrum and (c) TG-DSC curve of CBZ-DL-malic acid cocrystal.

Anti-solvent slurry experiment 8: CBZ-benzoic acid cocrystal (1:1)

An equimolar mixture of CBZ (13.2 mg, 0.056 mmol) and benzoic acid (6.8 mg, 0.056 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeCN/10 μ L EtOAc/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S8 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/benzoic acid system.

Anti-solvent slurry experiment 9: CBZ-cinnamic acid (1:1)

An equimolar mixture of CBZ (12.3 mg, 0.052 mmol) and cinnamic acid (7.7 mg, 0.052 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeCN/10 μ L EtOAc/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S9 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/cinnamic acid system.

Anti-solvent slurry experiment 10: CBZ-salicylic acid cocrystal (1:1)

An equimolar mixture of CBZ (12.6 mg, 0.053 mmol) and salicylic acid (7.4 mg, 0.054 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeCN/10 μ L EtOAc/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S10 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/salicylic acid system.

Anti-solvent slurry experiment 11: CBZ-acetylsalicylic acid cocrystal (1:1)

An equimolar mixture of CBZ (11.3 mg, 0.048 mmol) and acetylsalicylic acid (8.7 mg, 0.048 mmol) was added to 1 mL heptane with addition of 40 μ L MeOH/40 μ L MeOH/40 μ L MeOH/100 μ L EtOAc/40 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S11 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/acetylsalicylic acid system.

Anti-solvent slurry experiment 12: CBZ-1-hydroxy-2-naphthoic acid cocrystal (1:1)

An equimolar mixture of CBZ (11.1 mg, 0.047 mmol) and 1-hydroxy-2-naphthoic acid (8.9 mg, 0.047 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeOH/10 μ L MeOH/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S12 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/1-hydroxy-2-naphthoic acid system.

Anti-solvent slurry experiment 13: CBZ-4-hydroxybenzoic acid cocrystal (1:1)

An equimolar mixture of CBZ (12.6 mg, 0.053 mmol) and 4-hydroxybenzoic acid (7.4 mg, 0.053 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeOH/10 μ L MeOH/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S13 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/4-hydroxybenzoic acid system.

Anti-solvent slurry experiment 14: CBZ-vanillic acid cocrystal hydrate (1:1:1)

An equimolar mixture of CBZ (11.7 mg, 0.050 mmol) and vanillic acid (8.3 mg, 0.049 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/40 μ L MeCN/100 μ L EtOAc/100 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S14 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/vanillic acid system.

Anti-solvent slurry experiment 15: CBZ-2, 4-dihydroxybenzoic acid cocrystal (1:1)

An equimolar mixture of CBZ (12.1 mg, 0.051 mmol) and 2, 4-dihydroxybenzoic acid (7.9 mg, 0.051 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeOH/10 μ L MeOH/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S15 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/2, 4-

dihydroxybenzoic acid system.

Anti-solvent slurry experiment 16: CBZ-2, 5-dihydroxybenzoic acid cocrystal (1:1)

An equimolar mixture of CBZ (12.1 mg, 0.051 mmol) and 2, 5-dihydroxybenzoic acid (7.9 mg, 0.051 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeOH/10 μ L MeOH/10 μ L ACE and left to stir for 24 hours at room temperature.





Fig. S16 (a) PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/2, 5dihydroxybenzoic acid system. (b) ¹H NMR spectrum and (c) TG-DSC curve of the newly obtained hemihydrate of CBZ-2, 5-dihydroxybenzoic acid cocrystal during ASS with MeOH.

Anti-solvent slurry experiment 17: CBZ-2, 6-dihydroxybenzoic acid cocrystal (1:1)

An equimolar mixture of CBZ (12.1 mg, 0.051 mmol) and 2, 6-dihydroxybenzoic acid (7.9 mg, 0.051 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeOH/10 μ L MeOH/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S17 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/2, 6dihydroxybenzoic acid system.

Anti-solvent slurry experiment 18: CBZ-2, 6-pyridinedicarboxylic acid cocrystal (1:1)

An equimolar mixture of CBZ (11.7 mg, 0.050 mmol) and 2, 6-pyridinedicarboxylic acid (8.3 mg, 0.050 mmol) was added to 1 mL heptane with addition of 20 μ L MeOH/40 μ L MeOH/40 μ L EtOAc/10 μ L ACE and left to stir for 48 hours at room temperature.



Fig. S18 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/2, 6-pyridinedicarboxylic acid system.

Anti-solvent slurry experiment 19: CBZ-benzamide cocrystal (1:1)

An equimolar mixture of CBZ (13.2 mg, 0.056 mmol) and benzamide (6.8 mg, 0.056 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeCN/10 μ L EtOAc/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S19 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of

CBZ/benzamide system.

Anti-solvent slurry experiment 20: CBZ-isonicotinamide cocrystal (1:1)

An equimolar mixture of CBZ (13.2 mg, 0.056 mmol) and isonicotinamide (6.8 mg, 0.056 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeOH/10 μ L MeOH/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S20 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/ isonicotinamide system.

Anti-solvent slurry experiment 21: CBZ-nicotinamide cocrystal (1:1)

An equimolar mixture of CBZ (13.2 mg, 0.056 mmol) and nicotinamide (6.8 mg, 0.056 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeCN/10 μ L EtOAc/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S21 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/

nicotinamide system.

Anti-solvent slurry experiment 22: CBZ-4-hydroxybenzamide cocrystal (1:1) An equimolar mixture of CBZ (12.7 mg, 0.054 mmol) and 4-hydroxybenzamide (7.4 mg, 0.054 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeOH/10 μ L MeOH/10 μ L MeOH/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S22 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/4-hydroxybenzamide system.

Anti-solvent slurry experiment 23: CBZ-saccharin (1:1)

An equimolar mixture of CBZ (11.3 mg, 0.048 mmol) and saccharin (8.7 mg, 0.048 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeCN/10 μ L EtOAc/10 μ L ACE and left to stir for 24 hours at room temperature.



Fig. S23 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/saccharin system.

Anti-solvent slurry experiment 24: CBZ-4, 4'-bipyridine cocrystal (2:1)

A stoichiometric mixture of CBZ (15.0 mg, 0.063 mmol) and 4, 4'-bipyridine (5.0 mg, 0.032 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/10 μ L MeOH/10 μ L MeOH/10 μ L ACE and left to stir for 24 hours at room temperature.

Slurry experiment: CBZ-4, 4'-bipyridine cocrystal (2:1)

A stoichiometric mixture of CBZ (636.0 mg, 2.69 mmol) and 4, 4'-bipyridine (210.2 mg, 1.35 mmol) was added to 1 mL ACE and left to stir for 24 hours at room temperature.



Fig. S24 PXRD patterns of the outcome of (a) anti-solvent slurry (ASS) experiments and (b) slurry

experiments of CBZ/4, 4'-bipyridine system.

Anti-solvent slurry experiment 25: CBZ-naringenin cocrystal (1:1)

An equimolar mixture of CBZ (9.3 mg, 0.039 mmol) and naringenin (10.7 mg, 0.039 mmol) was added to 1 mL heptane with addition of 10 μ L MeOH/40 μ L MeCN/100 μ L EtOAc/100 μ L ACE and left to stir for 48 hours at room temperature.



Fig. S25 PXRD patterns of the outcome of anti-solvent slurry (ASS) experiments of CBZ/naringenin system.